BDSX vs. XGN, DCGO, EUDA, SERA, CORBF, QIPT, KDLY, NAKA, ATPC, and BMGL
Should you be buying Biodesix stock or one of its competitors? The main competitors of Biodesix include Exagen (XGN), DocGo (DCGO), EUDA Health (EUDA), Sera Prognostics (SERA), Global Cord Blood (CORBF), Quipt Home Medical (QIPT), Kindly MD (KDLY), KindlyMD (NAKA), Agape ATP (ATPC), and Basel Medical Group (BMGL). These companies are all part of the "healthcare" industry.
Biodesix vs. Its Competitors
Biodesix (NASDAQ:BDSX) and Exagen (NASDAQ:XGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.
In the previous week, Exagen had 1 more articles in the media than Biodesix. MarketBeat recorded 2 mentions for Exagen and 1 mentions for Biodesix. Biodesix's average media sentiment score of 1.87 beat Exagen's score of 0.94 indicating that Biodesix is being referred to more favorably in the media.
Biodesix has a beta of 0.97, meaning that its stock price is 3% less volatile than the S&P 500. Comparatively, Exagen has a beta of 1.58, meaning that its stock price is 58% more volatile than the S&P 500.
Exagen has a net margin of -27.34% compared to Biodesix's net margin of -54.28%. Exagen's return on equity of -133.69% beat Biodesix's return on equity.
Exagen has lower revenue, but higher earnings than Biodesix. Exagen is trading at a lower price-to-earnings ratio than Biodesix, indicating that it is currently the more affordable of the two stocks.
21.0% of Biodesix shares are held by institutional investors. Comparatively, 75.3% of Exagen shares are held by institutional investors. 30.1% of Biodesix shares are held by insiders. Comparatively, 12.6% of Exagen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Biodesix presently has a consensus target price of $1.75, suggesting a potential upside of 459.11%. Exagen has a consensus target price of $7.50, suggesting a potential upside of 4.31%. Given Biodesix's higher probable upside, equities research analysts clearly believe Biodesix is more favorable than Exagen.
Summary
Exagen beats Biodesix on 10 of the 16 factors compared between the two stocks.
Get Biodesix News Delivered to You Automatically
Sign up to receive the latest news and ratings for BDSX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BDSX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Biodesix Competitors List
Related Companies and Tools
This page (NASDAQ:BDSX) was last updated on 7/17/2025 by MarketBeat.com Staff
